Merck Reports the Data from P-III (KEYNOTE-522) Study of Keytruda for Treating Triple Negative Breast Cancer (TNBC)
Shots:
- The P-III (KEYNOTE-522) study assesses Keytruda + CT vs PBO + CT as neoadj. followed by Keytruda vs PBO as adj. therapy in TNBC patients (n=1,174)
- The study met its 1EP of OS, showing improvement at a pre-specified interim analysis. Data will be featured at future conferences & shared with regulatory bodies
- Keytruda is being assessed in KEYNOTE-242 (as adj. monotx. for TNBC with residual disease), KEYNOTE-756 (with CT for high-risk, early-stage ER+/HER2- breast cancer), TroFuse-010 (with sac-TMT vs sac-TMT alone & physician’s choice of therapy for unresectable locally advanced/metastatic ER+/HER2- breast cancer) & TroFuse-012 (with sac-TMT vs physician’s choice of therapy for TNBC patients receiving Keytruda based neoadj., not reached pCR at surgery)
Ref: Merck | Image: Merck
Related News:- Merck Reports Results from the P-III (KEYNOTE-B21) Study of Keytruda Plus Chemotherapy for Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
